汉森制药
(002412)
| 流通市值：34.80亿 | | | 总市值：35.17亿 |
| 流通股本：4.98亿 | | | 总股本：5.03亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 160,908,957.57 | 249,647,573.86 | 127,878,185.34 | 143,590,735.43 |
| 交易性金融资产 | 410,021,354.12 | 333,803,988.91 | 357,156,512.48 | 312,843,480.15 |
| 应收票据及应收账款 | 399,035,357.84 | 335,340,615.27 | 365,753,297.42 | 371,247,750.57 |
| 其中：应收票据 | 37,009,317.66 | 53,124,555.04 | 54,312,945.1 | 57,762,519.09 |
| 应收账款 | 362,026,040.18 | 282,216,060.23 | 311,440,352.32 | 313,485,231.48 |
| 应收款项融资 | 94,645,162.87 | 91,075,929.53 | 80,279,493.11 | 64,602,041.85 |
| 预付款项 | 3,306,745.76 | 3,258,521.14 | 4,380,374.51 | 2,586,093.31 |
| 其他应收款合计 | 7,836,411.71 | 11,295,808.93 | 16,384,639.66 | 20,403,526.21 |
| 其中:应收利息 | - | - | 397,867.8 | 198,933.9 |
| 存货 | 215,018,780.04 | 208,441,934.5 | 208,153,297.49 | 207,024,087.81 |
| 其他流动资产 | 87,009,294.3 | 88,952,302.83 | 85,505,145.16 | 103,284,892.16 |
| 流动资产合计 | 1,377,782,064.21 | 1,321,816,674.97 | 1,245,490,945.17 | 1,225,582,607.49 |
| 非流动资产: | | | | |
| 长期股权投资 | 827,976,210.77 | 836,439,276.36 | 771,817,988.28 | 797,726,445.52 |
| 投资性房地产 | 2,368,975.83 | 2,418,980.85 | 2,468,985.87 | 3,232,690.33 |
| 固定资产 | 429,278,782.48 | 436,300,945.95 | 442,779,369.73 | 451,252,000.7 |
| 在建工程 | 13,392,312.96 | 12,772,312.3 | 11,844,054.76 | 11,746,943.91 |
| 生产性生物资产 | 6,585,790.96 | 6,649,909.27 | 9,241,769.7 | 9,333,371.78 |
| 无形资产 | 28,761,133.78 | 28,660,731.1 | 28,937,302.44 | 28,555,510.01 |
| 商誉 | 14,730,798.93 | 14,730,798.93 | 14,789,430.33 | 14,789,430.33 |
| 长期待摊费用 | 14,730,422.03 | 14,938,784.36 | 15,147,146.69 | 14,903,381.96 |
| 递延所得税资产 | 2,117,139.06 | 2,241,887.42 | 2,224,503.49 | 2,295,352 |
| 其他非流动资产 | 15,695,541.16 | 16,103,645.17 | 17,744,619.98 | 15,914,244.98 |
| 非流动资产合计 | 1,355,637,107.96 | 1,371,257,271.71 | 1,316,995,171.27 | 1,349,749,371.52 |
| 资产总计 | 2,733,419,172.17 | 2,693,073,946.68 | 2,562,486,116.44 | 2,575,331,979.01 |
| 流动负债: | | | | |
| 短期借款 | 50,976,472.12 | 57,503,496.08 | 55,051,513.86 | 67,344,739.89 |
| 应付票据及应付账款 | 33,909,622.52 | 34,278,292.97 | 25,992,511.03 | 25,062,397.76 |
| 应付账款 | 33,909,622.52 | 34,278,292.97 | 25,992,511.03 | 25,062,397.76 |
| 合同负债 | 1,827,916.58 | 812,199.73 | 973,140.92 | 1,242,466.95 |
| 应付职工薪酬 | 17,395,009.64 | 40,564,999.05 | 17,791,677.86 | 17,949,706.76 |
| 应交税费 | 14,010,468.68 | 13,985,696.28 | 6,765,761.15 | 20,509,402.13 |
| 其他应付款合计 | 153,488,677.73 | 125,931,215.08 | 143,161,879.23 | 133,929,005.22 |
| 其他流动负债 | 15,558,777.4 | 15,253,200.96 | 27,602,645.64 | 28,888,357.75 |
| 流动负债合计 | 287,166,944.67 | 288,329,100.15 | 277,339,129.69 | 294,926,076.46 |
| 非流动负债: | | | | |
| 递延收益 | 22,493,127.41 | 23,013,753.92 | 23,455,433.06 | 23,822,112.2 |
| 递延所得税负债 | 831,201.71 | 807,487.77 | 866,390.24 | 868,696.93 |
| 非流动负债合计 | 23,324,329.12 | 23,821,241.69 | 24,321,823.3 | 24,690,809.13 |
| 负债合计 | 310,491,273.79 | 312,150,341.84 | 301,660,952.99 | 319,616,885.59 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 503,200,000 | 503,200,000 | 503,200,000 | 503,200,000 |
| 资本公积 | 234,116,276.27 | 234,116,276.27 | 234,116,276.27 | 234,116,276.27 |
| 其他综合收益 | 13,470,414.8 | 9,872,544.14 | 5,369,311.3 | 14,246,043.33 |
| 盈余公积 | 202,955,914.79 | 202,955,914.79 | 191,075,411.87 | 191,075,411.87 |
| 未分配利润 | 1,469,185,292.52 | 1,430,778,869.64 | 1,327,064,164.01 | 1,313,077,361.95 |
| 归属于母公司股东权益合计 | 2,422,927,898.38 | 2,380,923,604.84 | 2,260,825,163.45 | 2,255,715,093.42 |
| 股东权益合计 | 2,422,927,898.38 | 2,380,923,604.84 | 2,260,825,163.45 | 2,255,715,093.42 |
| 负债和股东权益合计 | 2,733,419,172.17 | 2,693,073,946.68 | 2,562,486,116.44 | 2,575,331,979.01 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-28 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |